The cases of hereditary angioedema are increasing. The hereditary nature of the disease is passing the defective gene to the upcoming generations. This is expected to drive the growth of the Hereditary Angioedema market. The non-profit organizations are supporting the research on the disease that may lead to further growth in the market. Recently on June 7 2022, BioCryst Pharmaceuticals Inc., a company that designs and develops small molecule medicines for such rare diseases, announced that Swissmedic which is the Swiss Surveillance authority for medicines and medical devices, had given permission for marketing of oral, once in a day ORLADEYO for preventing routine recurrent hereditary angioedema that targets patients 12 years or older in Switzerland. The major factor that inhibits growth of the market are misdiagnosis of the disease and high drug costs.
According to Coherent Market Insights, Global Aereditary Angioedema Market is estimated to be valued at US$ 2,431.89 million in 2022 and is expected to exhibit a CAGR of 9.1% during the forecast period (2022-2030)
Leading Companies in the Hereditary Angioedema Industry:
1. CSL Limited
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
2. Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
3. BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. It is a biotechnology company, discovers novel, oral, and small-molecule medicines.